Oncology approvals (and the undoing of an accelerated approval) and the US Food and Drug Administration clearance of a rare new molecular entity in hormonal contraception stood out in a week notably lacking in submission news.
Mayne Pharma USA and Mithra Pharmaceuticals SA’s Nextstellis combines a novel estrogen component – estetrol, or E4 –...





